Evidence map›Paper›PMID 42272773›Full record

ArticleOncology letters2026

Immune checkpoint inhibitors for invasive mucinous adenocarcinoma: A case series.

Tatsuya Kato, Takahiro Mitsumura, Eiyu Tsuboi, Hiroshi Nakahama, Yui Takahashi, Yuichiro Nei, Shigeo Hanada, Atsushi Miyamoto, Hironori Uruga, Takeshi Fujii and 1 more

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncology letters, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Tatsuya KatoDepartment of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105-8470, Japan.
Takahiro MitsumuraDepartment of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105-8470, Japan.
Eiyu TsuboiDepartment of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105-8470, Japan.
Hiroshi NakahamaDepartment of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105-8470, Japan.
Yui TakahashiDepartment of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105-8470, Japan.
Yuichiro NeiDepartment of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105-8470, Japan.
Shigeo HanadaDepartment of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105-8470, Japan.
Atsushi MiyamotoDepartment of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105-8470, Japan.
Hironori UrugaDepartment of Diagnostic Pathology, Toranomon Hospital, Tokyo 105-8470, Japan.
Takeshi FujiiDepartment of Diagnostic Pathology, Toranomon Hospital, Tokyo 105-8470, Japan.
Meiyo TamaokaDepartment of Respiratory Medicine, Respiratory Center, Toranomon Hospital, Tokyo 105-8470, Japan.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Invasive mucinous adenocarcinoma (IMA) is a rare subtype of lung adenocarcinoma that frequently harbors

Indexed as

immune checkpoint inhibitorinvasive mucinous adenocarcinomaKRAS

Identifiers

PMID42272773
PMCPMC13247393

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.